Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis

Autor: Josef S Smolen, Dave Nicholls, Daniel Aletaha, Jen-Fue Maa, Stefan Florentinus, Sung-Hwan Park, Su Chen, Daniel Furtner

Publikováno v: Annals of the Rheumatic Diseases

ObjectivesTo determine if disease duration and number of prior disease-modifying antirheumatic drugs (DMARDs) affect response to therapy in patients with established rheumatoid arthritis (RA).MethodsAssociations between disease duration or number of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fea52036428ba55e4b153f0749b153d9
https://doi.org/10.1136/annrheumdis-2018-214918

Testing Treat-to-Target Outcomes With Initial Methotrexate Monotherapy Compared With Initial Tumor Necrosis Factor Inhibitor (Adalimumab) Plus Methotrexate in Early Rheumatoid Arthritis

Autor: Ronald F van Vollenhoven, I. Sainsbury, Stefan Florentinus, Benoît Guérette, Josef S Smolen, Paul Emery, Arthur Kavanaugh, Hartmut Kupper, Su Chen, Roy Fleischmann

Publikováno v: Kavanaugh, A, van Vollenhoven, R F, Fleischmann, R, Emery, P, Sainsbury, I, Florentinus, S, Chen, S, Guérette, B, Kupper, H & Smolen, J S 2018, ' Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis ', Annals of the Rheumatic Diseases, vol. 77, no. 2, pp. 289-292 . https://doi.org/10.1136/annrheumdis-2017-211871
Annals of the rheumatic diseases, 77(2), 289-292. BMJ Publishing Group
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 77(2), 289-292. BMJ Publishing Group

ObjectivesTo compare responses in patients with early rheumatoid arthritis (RA) initially treated with the tumour necrosis factor inhibitor (TNFi) adalimumab+methotrexate (MTX) versus MTX monotherapy who may have continued receiving MTX or switched t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d7df1ac7889de9099702bdccc5172c
https://eprints.whiterose.ac.uk/123549/9/289.full.pdf

SAT0142 Predictors of inadequate response and rapid radiographic progression in patients with early rheumatoid arthritis receiving methotrexate: a post hoc analysis of 2 randomized, controlled trials of adalimumab

Autor: Stefan Florentinus, Josef S Smolen, BA Wolfe, Su Chen, J. Suboticki, A. Kavanaugh, R. van Vollenhoven

Publikováno v: Poster Presentations.

Background Methotrexate (MTX) is recommended as first-line therapy in patients (pts) with rheumatoid arthritis (RA). 1 However, information is limited regarding factors that may predict a poor response to MTX. Objectives To identify predictors of MTX

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4bb2c014b3dd64e3694797457af68afd
https://doi.org/10.1136/annrheumdis-2017-eular.1892

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone

Autor: I. Sainsbury, Désirée van der Heijde, Ronald F van Vollenhoven, Hartmut Kupper, Kun Chen, Ferdinand C. Breedveld, Josef S Smolen, Edward C. Keystone, Paul Emery, Arthur Kavanaugh, Stefan Florentinus

Publikováno v: RMD open, 3(2). BMJ Publishing Group
RMD Open, 3(2):e000445. BMJ Publishing Group
Keystone, E C, Breedveld, F C, Heijde, D V D, Van Vollenhoven, R F, Emery, P, Smolen, J S, Sainsbury, I, Florentinus, S, Kupper, H, Chen, K & Kavanaugh, A 2017, ' Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone ', RMD Open, vol. 3, no. 2, e000445 . https://doi.org/10.1136/rmdopen-2017-000445
RMD Open

Objective To evaluate the achievement of comprehensive disease control (CDC) following 1 year of treatment with adalimumab+methotrexate versus methotrexate alone and whether early achievement of remission (at week 24 or 26) is associated with CDC at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6021f3bde57977a3d8afa9e3da57825
https://pure.amc.nl/en/publications/achieving-comprehensive-disease-control-in-patients-with-early-and-established-rheumatoid-arthritis-treated-with-adalimumab-plus-methotrexate-versus-methotrexate-alone(924de577-3758-40b0-8cb4-787dc46025a9).html

Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis

Autor: Benoît Guérette, Josef S Smolen, Désirée van der Heijde, Su Chen, Stefan Florentinus, Robert Landewé

Publikováno v: Arthritis Research & Therapy

Introduction Clinical synovitis is often associated with damage to bone and cartilage. Previous data have suggested that joint erosions (JE) are more prevalent than joint space narrowing (JSN) and that the two processes are partly independent of each

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b69d855bd497efdfcec0ad24b64aaa9
https://doi.org/10.1186/s13075-015-0626-1